The development of chemotherapy regimens for non-small cell lung cancer must be based on the specific pathological type of the patient’s lung cancer, the individual’s physical condition and at different stages of treatment. One of the most common is sensitive driver mutation negative lung adenocarcinoma, in which case pemetrexed, plus platinum-based combination chemotherapy regimen is clinically preferred in the first line. If the patient is in better health and financially able, bevacizumab will also be added at this time. If this regimen fails or progresses to the second line, more vincristine drugs are used. Specifically for squamous lung cancer, paclitaxel or albumin paclitaxel-based drugs combined with platinum-based therapy are preferred, and gemcitabine drugs combined with platinum-based therapy are also available. Some patients who are not in good health can be treated with paclitaxel, gemcitabine, and vincristine chemotherapy drugs alone. In short, the decision should be based on the specific type of pathology, the patient’s physical condition, and other factors.